137 related articles for article (PubMed ID: 30849062)
1. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.
Boland X; Chhabra P
J Psychiatr Pract; 2019 Mar; 25(2):135-138. PubMed ID: 30849062
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
3. Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Chavez B; Poveda RA
Ann Pharmacother; 2006 Dec; 40(12):2265-8. PubMed ID: 17119107
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
Cheng Z; Yuan Y; Han X; Yang L; Cai S; Yang F; Lu Z; Wang C; Deng H; Zhao J; Xiang Y; Correll CU; Yu X
J Psychopharmacol; 2019 Oct; 33(10):1227-1236. PubMed ID: 31487208
[TBL] [Abstract][Full Text] [Related]
5. c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences.
Kiss A; Osacka J
Endocr Regul; 2020 Jan; 54(1):43-52. PubMed ID: 32597143
[TBL] [Abstract][Full Text] [Related]
6. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
7. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Ganguli R; Brar JS; Garbut R; Chang CC; Basu R
Clin Schizophr Relat Psychoses; 2011 Jul; 5(2):75-9. PubMed ID: 21693430
[TBL] [Abstract][Full Text] [Related]
8. Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus.
Kiss A; Osacka J
Endocr Regul; 2020 Apr; 54(2):77-84. PubMed ID: 32597151
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Gaebel W; Verde PE; Kolbe H; Correll CU; Leucht S; Heres S; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl T; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Wobrock T; Cordes J
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):83-94. PubMed ID: 31486890
[TBL] [Abstract][Full Text] [Related]
10. Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.
Yuan T; Wang S; Le J; Li Y
J Clin Pharmacol; 2020 Oct; 60(10):1355-1361. PubMed ID: 32428979
[TBL] [Abstract][Full Text] [Related]
11. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.
Naono-Nagatomo K; Naono H; Abe H; Takeda R; Funahashi H; Uchimura D; Ishida Y
Asian J Psychiatr; 2017 Feb; 25():36-41. PubMed ID: 28262171
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Hashimoto N; Toyomaki A; Miyamoto T; Miyazaki A; Kuksumi I
Schizophr Res; 2018 Jul; 197():587-588. PubMed ID: 29223323
[No Abstract] [Full Text] [Related]
13. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder.
Feeley RJ; Arnaout B; Yoon G
J Clin Psychopharmacol; 2017 Dec; 37(6):729-730. PubMed ID: 29028689
[No Abstract] [Full Text] [Related]
14. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
15. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Fujiyama H; Sugawara H; Kanno T; Kawahara K; Tanaka H; Fukuhara R; Boku S; Takebayashi M
Psychiatry Clin Neurosci; 2020 Dec; 74(12):666-667. PubMed ID: 32909325
[No Abstract] [Full Text] [Related]
18. Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and γ-aminobutyric acid A receptors in nucleus accumbens of juvenile rats.
Pan B; Lian J; Deng C
J Psychopharmacol; 2018 Nov; 32(11):1252-1263. PubMed ID: 30136620
[TBL] [Abstract][Full Text] [Related]
19. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
20. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
